CBSET, Inc.
↗Lexington, USA
CBSET, Inc. is a preclinical translational research institute based in Lexington, Massachusetts. It operates as a contract research organization (CRO) specializing in the advancement of early-stage biomedical technologies, particularly in the fields of interventional cardiology, structural heart, and cardiovascular medicine.
The company provides a comprehensive range of services, including GLP and non-GLP in-vivo studies, histopathology, morphometry, and regulatory consulting. CBSET serves medical device, pharmaceutical, and academic organizations by combining preclinical research expertise with operational support to accelerate the development of innovative treatments and diagnostic tools.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2006
Ownership:subsidiary
Status:operating
FUNDING
Investors:Arlington Capital Partners
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service Provider)
Modalities:Medical Devices, Small molecule, Cell therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Arlington Capital Partners
Acquired By:Arlington Capital Partners (2025-10-01)
Key Partnerships:CILcare (Preclinical research for hearing disorders)
COMPETITION
Position:Niche Player
Competitors:Charles River Laboratories, Labcorp
LEADERSHIP
Key Executives:
Michael C. John - Chief Regulatory and Innovation Officer (CRIO)
LINKS
Website:cbset.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CBSET, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CBSET, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.